S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Intra-Cellular TherapiesAdvanz PharmaRevance TherapeuticsAptorum GroupKaruna Therapeutics
SymbolNASDAQ:ITCIOTCMKTS:CXRXFNASDAQ:RVNCNASDAQ:APMNASDAQ:KRTX
Price Information
Current Price$8.37$12.02$15.67$15.99$14.82
52 Week RangeBuyHoldBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$25.14N/A$34.10$22.00$32.25
% Upside from Price Target200.39% upsideN/A117.64% upside37.59% upside117.61% upside
Trade Information
Market Cap$457.91 million$587.99 million$676.09 million$462.14 million$311.15 million
Beta1.160.581.14N/AN/A
Average Volume703,164186420,6022,50198,928
Sales & Book Value
Annual Revenue$250,000.00$536.99 million$3.73 million$380,000.00N/A
Price / Sales1,847.191.09185.281,219.03N/A
CashflowN/A$8.90 per shareN/AN/AN/A
Price / CashN/A1.35N/AN/AN/A
Book Value$5.81 per share$4.02 per share$3.94 per share$1.13 per shareN/A
Price / Book1.442.993.9814.15N/A
Profitability
Net Income$-155,130,000.00$1.47 billion$-142,570,000.00$-14,830,000.00N/A
EPS($2.84)$11.78($3.94)N/AN/A
Trailing P/E RatioN/A1.02N/A0.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A322.43%-3,745.97%N/AN/A
Return on Equity (ROE)-50.81%-60.90%-79.28%N/AN/A
Return on Assets (ROA)-44.29%-6.91%-54.14%N/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.08%9.26%0.15%0.01%N/A
Current Ratio8.86%2.33%5.59%12.97%34.75%
Quick Ratio8.86%1.98%5.59%12.91%34.75%
Ownership Information
Institutional Ownership Percentage69.06%N/A98.75%0.04%36.98%
Insider Ownership Percentage18.20%N/A5.20%N/AN/A
Miscellaneous
Employees734351703913
Shares Outstanding55.17 million48.91 million44.10 million28.97 million23.41 million
Next Earnings Date11/6/2019 (Estimated)11/13/2019 (Estimated)11/7/2019 (Estimated)N/A11/14/2019 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
 Intra-Cellular TherapiesAdvanz PharmaRevance TherapeuticsAptorum GroupKaruna Therapeutics

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel